New

Evalus AI

The AI engine Fit Assessment

Beta

The company provides pharma-focused technology solutions for late-phase clinical trials, including RWE, PMS, registries, and modular tools (EDC, CTMS, ePRO, eTMF, eConsent, remote patient monitoring) with regulatory-compliant standards (21 CFR Part 11, ICH-GCP, HIPAA, EU-GDPR, ISO 27001) and India-based, globally scalable operations.

Blurb

Real-World Research. Delivered with Scientific Rigour and Operational Clarity.

HQ Location

undefined, undefined

Founded

Not available

Employees

51 - 200

Total funding raised

Not available

Funding Status

Not available

Real-World Research. Delivered with Scientific Rigour and Operational Clarity.



At Evalus AI, we help pharmaceutical, biotech, and medical device companies run smarter late-phase studies. Whether it's Real-World Evidence (RWE), PMS, registries, or long-term observational trials, our platform makes complex research simpler, faster, and fully compliant.



Evalus offers a modular suite of validated tools tailored for late-phase research and real-world settings. Our platform enables sponsors to streamline data collection, ensure regulatory alignment, and reduce operational complexity.



Our product includes:

• Electronic Data Capture (EDC)

• Clinical Trial Management System (CTMS)

• Electronic Patient-Reported Outcomes (ePRO)

• Electronic Trial Master File (eTMF)

• eConsent and Remote Patient Monitoring



All modules are built in accordance with 21 CFR Part 11, ICH-GCP, HIPAA, EU-GDPR, and ISO 27001 standards.



Our technology-enabled workflows accelerate data capture and improve data quality while keeping study teams inspection-ready at all times.



Why Choose Evalus?

• Purpose-built for late-phase and RWE studies

• Modular, interoperable digital platform

• Built by regulatory and scientific experts

• Strong compliance foundation

• India-based operations, globally scalable execution



From protocol design to publication, Evalus brings together regulatory precision, scientific clarity, and operational flexibility, helping our clients turn post-approval data into meaningful, measurable insights.